Given the limited administration frequency possible with catheter-based delivery approaches, a notable trend in intravesical therapy has been directed toward extending the contact time between the therapeutic agent and the tumor.
← all excerpts
Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024.
1
—
—